Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2024 08:19 ET | Source: Research and Markets

Global Caspofungin Market Projected to Hit USD 590.5 Million by 2034, Asia Pacific Region to Witness Highest Growth Rate

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Caspofungin Market" report has been added to ResearchAndMarkets.com's offering. New insights into the global caspofungin market have been...
January 04, 2022 05:58 ET | Source: Research and Markets

Insights on the Antifungal Drug Global Market to 2026 - Featuring Abbott Laboratories, Astellas Pharma and Cipla Among Others

Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region - Global Forecast to 2026 - Cumulative Impact...
August 20, 2021 08:18 ET | Source: Research and Markets

Global Antifungal Drug Markets Analysis & Forecasts 2021-2026 - Focus on Echinocandins, Azoles, Polyenes, Allylamines

Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Antifungal Drug Market (2021-2026) by Drug Type, Indication, Dosage Form, Distribution Channel, Geography, Competitive Analysis and the Impact...
August 08, 2019 16:07 ET | Source: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
August 07, 2019 07:30 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
July 29, 2019 07:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...